ArticleMethods in molecular biology (Clifton, N.J.)2021
Genetic Transformation of Trichoderma spp.
Article in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Exploring salicylic acid biosynthesis in Trichoderma spp. using an enhanced transformation approach.Fungal biology and biotechnology · 2026Article
- Regulatory adaptation of an accessory gene controls fungal halotolerance and niche expansion.The ISME journal · 2026Article
- Providing a toolbox for genomic engineering ofMicrobiology spectrum · 2025Article
- Protocol for generating protoplasts of Trichoderma koningiopsis and transformation of plasmid DNA.STAR protocols · 2025Article
- Genomic Characterization and Establishment of a Genetic Manipulation System forJournal of fungi (Basel, Switzerland) · 2024Article
- Growth, Enzymatic, and Transcriptomic Analysis ofBiomolecules · 2024Article
- Strain improvement ofFrontiers in microbiology · 2023Review
- Use of CRISPR-Cas tools to engineer Trichoderma species.Microbial biotechnology · 2022Review
- The hidden power of secondary metabolites in plant-fungi interactions and sustainable phytoremediation.Frontiers in plant science · 2022Review
- An overview on current molecular tools for heterologous gene expression in Trichoderma.Fungal biology and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The production of biofuels from plant biomass is dependent on the availability of enzymes that can hydrolyze the plant cell wall polysaccharides to their monosaccharides. These enzyme mixtures are formed by microorganisms but their native compositions and properties are often not ideal for application. Genetic engineering of these microorganisms is therefore necessary, in which introduction of DNA is an essential precondition. The filamentous fungus Trichoderma reesei-the main producer of plant-cell-wall-degrading enzymes for biofuels and other industries-has been subjected to intensive genetic engineering toward this goal and has become one of the iconic examples of the successful genetic improvement of fungi. However, the genetic manipulation of other enzyme-producing Trichoderma species is frequently less efficient and, therefore, rarely managed. In this chapter, we therefore describe the two potent methods of Trichoderma transformation mediated by either (a) polyethylene glycol (PEG) or (b) Agrobacterium. The methods are optimized for T. reesei but can also be applied for such transformation-resilient species as T. harzianum and T. guizhouense, which are putative upcoming alternatives for T. reesei in this field. The protocols are simple, do not require extensive training or special equipment, and can be further adjusted for T. reesei mutants with particular properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.